Lyme Disease Diagnostic
Lyme Disease
Research/Proof-of-ConceptActive
Key Facts
About BlueArc Biosciences
BlueArc Biosciences is a private, pre-revenue biotech firm founded in 2018, focusing on the diagnostics sector with a core platform in synthetic biology-enabled biosensors. The company's primary mission is to develop novel biosensor technologies aimed at improving diagnostic capabilities, with initial recognition coming from a LymeX Phase I prize. While the provided data shows a discrepancy between a description mentioning small molecule therapeutics and the website's focus on diagnostics, the website content is taken as the primary source, indicating a diagnostics and biosensor platform company. The company appears to be in an early R&D stage, building its technology foundation.
View full company profileTherapeutic Areas
Other Lyme Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| VLA15 | Valneva | Phase 3 |
| Lyme Disease and Coinfections Diagnostics | Fry Laboratories | Commercial |
| Lyme Disease Vaccine | CyanVac | Preclinical |
| Next-Gen Lyme Test | Kephera Diagnostics | Development/Validation |
| Lyme Disease Diagnostic Personalization | Innatoss Laboratories | Research |